{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T07:03:12Z","timestamp":1794553392542,"version":"4.9.1"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,2,25]],"date-time":"2024-02-25T00:00:00Z","timestamp":1708819200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"AstraZeneca AB"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Beyond prevention of organ damage, treatment goals in SLE include optimization of health-related quality of life (HRQoL). The Lupus Low Disease Activity State (LLDAS) has received increasing attention as a goal whenever remission cannot be achieved. How SLE disease activity, organ damage and LLDAS attainment relate to patient-reported outcomes (PROs) is not fully explored, which formed the scope of this investigation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included 327 patients with SLE from a tertiary referral centre. Longitudinal registrations of disease activity using SLEDAI-2K and physician global assessment (PhGA), organ damage using the SLICC\/ACR damage index (SDI), pharmacotherapies, EQ-5D-3L data, as well as visual analogue scale (VAS) scores for fatigue, pain and overall SLE-related health state over a median follow-up time of 8.5\u2009years were analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the overall population, as well as subgroups of patients with recent-onset SLE and those with clinically active, autoantibody-positive disease, LLDAS attainment, lower PhGA and lower clinical SLEDAI-2K scores were associated with favourable HRQoL by EQ-5D-3L and VAS assessments, while increasing SDI scores were associated with poor PROs except for fatigue in the overall population. PROs were further enhanced by being in LLDAS sustainedly. In fully adjusted models of the entire study population, LLDAS attainment and lower disease activity were associated with favourable PROs, irrespective of SDI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In one of the longest observational studies to date, we demonstrated that low disease activity and being sustainedly in LLDAS were coupled with favourable HRQoL, pain, fatigue and overall health experience, irrespective of organ damage.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae120","type":"journal-article","created":{"date-parts":[[2024,2,25]],"date-time":"2024-02-25T06:35:43Z","timestamp":1708842943000},"page":"639-647","source":"Crossref","is-referenced-by-count":29,"title":["Lupus Low Disease Activity State and organ damage in relation to quality of life in systemic lupus erythematosus: a cohort study with up to 11 years of follow-up"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4875-5395","authenticated-orcid":false,"given":"Ioannis","family":"Parodis","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet , Stockholm,","place":["Sweden"]},{"name":"Department of Gastroenterology, Dermatology, and Rheumatology, Karolinska University Hospital , Stockholm,","place":["Sweden"]},{"name":"Department of Rheumatology, Faculty of Medicine and Health, \u00d6rebro University , \u00d6rebro,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Haugli-Stephens","sequence":"additional","affiliation":[{"name":"Health Economics, AstraZeneca AS , Oslo,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annica","family":"Dominicus","sequence":"additional","affiliation":[{"name":"SDS Life Science AB , Sankt Eriksgatan 113 , Stockholm,","place":["Sweden"]},{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Eek","sequence":"additional","affiliation":[{"name":"Respiratory and Immunology, Medical Department, BioPharmaceuticals, AstraZeneca , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0900-2048","authenticated-orcid":false,"given":"Christopher","family":"Sj\u00f6wall","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection, Link\u00f6ping University , Link\u00f6ping,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,24]]},"reference":[{"key":"2025032905211891100_keae120-B1","doi-asserted-by":"crossref","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic lupus erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2025032905211891100_keae120-B2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025032905211891100_keae120-B3","first-page":"1955","article-title":"Accrual of organ damage over time in patients with systemic lupus erythematosus","volume":"30","author":"Gladman","year":"2003","journal-title":"J Rheumatol"},{"key":"2025032905211891100_keae120-B4","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/rheumatology\/ker368","article-title":"Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort","volume":"51","author":"Lopez","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2025032905211891100_keae120-B5","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1177\/0961203310366572","article-title":"Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus","volume":"19","author":"Nossent","year":"2010","journal-title":"Lupus"},{"key":"2025032905211891100_keae120-B6","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1093\/rheumatology\/keh238","article-title":"Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus\u2014a 5-yr prospective study","volume":"43","author":"Stoll","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"2025032905211891100_keae120-B7","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1136\/annrheumdis-2013-204620","article-title":"The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort","volume":"74","author":"Ugarte-Gil","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025032905211891100_keae120-B8","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.autrev.2003.11.005","article-title":"What have we learned from a 10-year experience with the LUMINA (Lupus in Minorities; Nature vs. nurture) cohort? Where are we heading?","volume":"3","author":"Uribe","year":"2004","journal-title":"Autoimmun Rev"},{"key":"2025032905211891100_keae120-B9","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12891-015-0621-3","article-title":"Quality of life and acquired organ damage are intimately related to activity limitations in patients with systemic lupus erythematosus","volume":"16","author":"Bjork","year":"2015","journal-title":"BMC Musculoskelet Disord"},{"key":"2025032905211891100_keae120-B10","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1136\/annrheumdis-2013-205171","article-title":"Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort","volume":"74","author":"Bruce","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025032905211891100_keae120-B11","doi-asserted-by":"crossref","first-page":"651249","DOI":"10.3389\/fmed.2021.651249","article-title":"Adverse Health-Related Quality of Life Outcome Despite Adequate Clinical Response to Treatment in Systemic Lupus Erythematosus","volume":"8","author":"Gomez","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2025032905211891100_keae120-B12","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/0961203317722412","article-title":"Discordance of patient and physician health status concerns in systemic lupus erythematosus","volume":"27","author":"Golder","year":"2018","journal-title":"Lupus"},{"key":"2025032905211891100_keae120-B13","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1177\/0961203310378668","article-title":"Patient perspective of systemic lupus erythematosus in relation to health-related quality of life concepts: a qualitative study","volume":"19","author":"McElhone","year":"2010","journal-title":"Lupus"},{"key":"2025032905211891100_keae120-B14","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3109\/03009742.2012.677857","article-title":"An exploration of patient-reported symptoms in systemic lupus erythematosus and the relationship to health-related quality of life","volume":"41","author":"Pettersson","year":"2012","journal-title":"Scand J Rheumatol"},{"key":"2025032905211891100_keae120-B15","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1007\/s10067-021-05982-3","article-title":"Comparing longitudinal patient-reported outcome measures between Swedish patients with recent-onset systemic lupus erythematosus and early rheumatoid arthritis","volume":"41","author":"Heijke","year":"2022","journal-title":"Clin Rheumatol"},{"key":"2025032905211891100_keae120-B16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pec.2010.08.005","article-title":"The role of patient attachment and working alliance on patient adherence, satisfaction, and health-related quality of life in lupus treatment","volume":"85","author":"Bennett","year":"2011","journal-title":"Patient Educ Couns"},{"key":"2025032905211891100_keae120-B17","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.3390\/jcm11071857","article-title":"How can we enhance adherence to medications in patients with systemic lupus erythematosus? Results from a qualitative study","volume":"11","author":"Emamikia","year":"2022","journal-title":"J Clin Med"},{"key":"2025032905211891100_keae120-B18","first-page":"504","article-title":"Outcome measures to be used in clinical trials in systemic lupus erythematosus","volume":"26","author":"Smolen","year":"1999","journal-title":"J Rheumatol"},{"key":"2025032905211891100_keae120-B19","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/S2665-9913(19)30037-2","article-title":"Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study","volume":"1","author":"Golder","year":"2019","journal-title":"Lancet Rheum"},{"key":"2025032905211891100_keae120-B20","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000538","article-title":"DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2025032905211891100_keae120-B21","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","article-title":"Treat-to-target in systemic lupus erythematosus: recommendations from an international task force","volume":"73","author":"van Vollenhoven","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2025032905211891100_keae120-B22","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025032905211891100_keae120-B23","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard-2022-222487","article-title":"Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort","volume":"81","author":"Ugarte-Gil","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025032905211891100_keae120-B24","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1016\/S2665-9913(19)30049-9","article-title":"Definitions of remission in systemic lupus erythematosus: a post-hoc analysis of two randomised clinical trials","volume":"1","author":"Parodis","year":"2019","journal-title":"Lancet Rheum"},{"key":"2025032905211891100_keae120-B25","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/acr.23867","article-title":"Association of Achieving Lupus Low Disease Activity State Fifty Percent of the Time With Both Reduced Damage Accrual and Mortality in Patients With Systemic Lupus Erythematosus","volume":"72","author":"Sharma","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025032905211891100_keae120-B26","doi-asserted-by":"crossref","first-page":"E822","DOI":"10.1016\/S2665-9913(22)00304-6","article-title":"Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study","volume":"4","author":"Kandane-Rathnayake","year":"2022","journal-title":"Lancet Rheum"},{"key":"2025032905211891100_keae120-B27","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13075-017-1256-6","article-title":"Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study","volume":"19","author":"Golder","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2025032905211891100_keae120-B28","doi-asserted-by":"crossref","first-page":"4752","DOI":"10.1093\/rheumatology\/keac185","article-title":"Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus","volume":"61","author":"Emamikia","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025032905211891100_keae120-B29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13075-015-0521-9","article-title":"Application of the 2012 Systemic Lupus International Collaborating Clinics classification criteria to patients in a regional Swedish systemic lupus erythematosus register","volume":"17","author":"Ighe","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2025032905211891100_keae120-B30","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/acr2.11585","article-title":"Epidemiology and Damage accrual of Systemic Lupus Erythematosus in Central Sweden: a single-center population-based cohort study over 14 years from \u00d6sterg\u00f6tland County","volume":"5","author":"Arkema","year":"2023","journal-title":"ACR Open Rheumatol"},{"key":"2025032905211891100_keae120-B31","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"2025032905211891100_keae120-B32","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa051135","article-title":"Combined oral contraceptives in women with systemic lupus erythematosus","volume":"353","author":"Petri","year":"2005","journal-title":"N Engl J Med"},{"key":"2025032905211891100_keae120-B33","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/art.1780390303","article-title":"The development and initial validation of the Systemic Lupus International Collaborating Clinics\/American College of Rheumatology damage index for systemic lupus erythematosus","volume":"39","author":"Gladman","year":"1996","journal-title":"Arthritis Rheum"},{"key":"2025032905211891100_keae120-B34","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"key":"2025032905211891100_keae120-B35","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/MLR.0b013e3181c162a2","article-title":"Using instrument-defined health state transitions to estimate minimally important differences for four preference-based health-related quality of life instruments","volume":"48","author":"Luo","year":"2010","journal-title":"Med Care"},{"key":"2025032905211891100_keae120-B36","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3899\/jrheum.090764","article-title":"Comparison of the construct validity and sensitivity to change of the visual analog scale and a modified rating scale as measures of patient global assessment in rheumatoid arthritis","volume":"37","author":"Lati","year":"2010","journal-title":"J Rheumatol"},{"key":"2025032905211891100_keae120-B37","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1177\/0961203320912338","article-title":"Relationship between remission, disease activity and patient-reported outcome measures in patients with recent-onset systemic lupus erythematosus","volume":"29","author":"Heijke","year":"2020","journal-title":"Lupus"},{"key":"2025032905211891100_keae120-B38","doi-asserted-by":"crossref","first-page":"e000303","DOI":"10.1136\/lupus-2018-000303","article-title":"10 most important contemporary challenges in the management of SLE","volume":"6","author":"Felten","year":"2019","journal-title":"Lupus Sci Med"},{"key":"2025032905211891100_keae120-B39","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/14712598.2019.1561856","article-title":"Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies","volume":"19","author":"Parodis","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"2025032905211891100_keae120-B40","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0168-8510(00)00111-1","article-title":"Health-related quality of life by disease and socio-economic group in the general population in Sweden","volume":"55","author":"Burstrom","year":"2001","journal-title":"Health Policy"},{"key":"2025032905211891100_keae120-B41","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s13075-020-02334-5","article-title":"Articular involvement, steroid treatment and fibromyalgia are the main determinants of patient-physician discordance in systemic lupus erythematosus","volume":"22","author":"Elefante","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2025032905211891100_keae120-B42","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/annrheumdis-2016-209519","article-title":"A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)","volume":"76","author":"van Vollenhoven","year":"2017","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae120\/56991488\/keae120.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/2\/639\/56991488\/keae120.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/2\/639\/56991488\/keae120.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T23:34:48Z","timestamp":1743377688000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/2\/639\/7613960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,24]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,24]]},"published-print":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae120","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,2,24]]}}}